On December 11, Kexing Holding Biotechnology Co., Ltd. stated that it had obtained the new crown virus Omicron (Omicron) variant on December 5 with the assistance of relevant national ministries and commissions, relevant departments of the Hong Kong Special Administrative Region and partners. Nasopharyngeal swab specimens from infected persons, and the team of Professor Qin Chuan from the Institute of Medical Laboratory Animals of the Chinese Academy of Medical Sciences carried out virus isolation and full-gene sequencing work. So far, the Omi Keron mutant strain has been successfully isolated and the sequencing results have been obtained.
At the same time, Kexing Company introduced a sample of the Omi Keron mutant strain isolated from the University of Hong Kong, which arrived in Beijing on the afternoon of December 9 and transferred it to the P3 Laboratory of the Institute of Medical Laboratory Animals of the Chinese Academy of Medical Sciences for research.
Kexing said that after obtaining the new crown virus Omi Keron variant, it can better guarantee the development of vaccine cross-neutralization tests and vaccine strain screening, so as to understand the effect of the Omi Keron variant on the existing new crown vaccine. Impact, and then to evaluate the necessity of developing a vaccine against a variant strain of the new coronavirus Omi Keron.
According to Xinhua News Agency, South Africa’s Health Minister Joe Fahra said on the 10th that preliminary evidence shows that the risk of secondary infection caused by the Omi Kiron strain may be higher than other variants of the new coronavirus that “need attention”.
Reporter Liu Suya